To start your customized experience click the start button
Customize ?  
Cancer Types
Quick Links
Award Programs
About Us
Contact Us
Privacy Policy
Terms & Conditions
Face Book
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.


Jason M. Broderick
The breakthrough designation will expedite the development and review of this novel T-cell therapy in synovial sarcoma.
Silas Inman
The approval of Halaven was based on an improvement in overall survival (OS) in a phase 3 study.
Andrew J. Roth
Based on this study, the monoclonal antibody is being investigated in an ongoing phase 3 study and has received an FDA Breakthrough Therapy Designation.
Jason M. Broderick
The approval is based on results from the phase 3 ET743-SAR-3007 trial.
Letitia L. Star
Caregivers may grapple with practical and emotional challenges as they help loved ones manage cancer-related pain.
Silas Inman
Treatment with eribulin mesylate significantly extended overall survival (OS) compared with dacarbazine in patients with advanced soft tissue sarcoma, according to topline results from a phase 3 clinical trial.
Jason M. Broderick
The Food and Drug Administration (FDA) granted a priority review to Yondelis to treat patients with the disease, including liposarcoma and leiomyosarcoma subtypes, who have previously received chemotherapy that included an anthracycline. The FDA will make its final approval decision within six months.
Anita T. Shaffer
The Food and Drug Administration's calendar for making decisions on new cancer drugs and indications is taking shape for 2015, and the clock is ticking on at least 13 applications for novel agents and new therapeutic settings for existing drugs.
Peter L. Saltonstall
NORD was founded in 1983 by parents of children with rare diseases. Over the past 30 years, it has become a powerful advocacy voice for all patients with rare diseases, including cancer.
Charlotte Huff
Finding specialized care is worth the effort for patients with uncommon cancers.

Sign In

Not a member? Sign up now!
Continue without login

Sign Up

Patient Caregiver Advocate Other